EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Multiple Sclerosis with IFN-Bpros and cons



Treatment of Multiple Sclerosis with IFN-Bpros and cons



Journal of Interferon & Cytokine Research 22(Supplement 1): S-41




(PDF 0-2 workdays service: $29.90)

Accession: 035980539

Download citation: RISBibTeXText



Related references

Treatment of multiple sclerosis with various interferons: the cons. Neurology 38(7 Suppl 2): 62-65, 1988

Early immunomodulatory treatment of multiple sclerosis: pros and cons. Neurologia i Neurochirurgia Polska 37(4): 777-782, 2004

The pros and cons of early treatment of relapsing forms of multiple sclerosis. Journal of Neurology 251 Suppl 4: Iv30-Iv34, 2004

Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. European Neurology 56(2): 78-105, 2006

Cyclosporine and multiple sclerosis: the cons. Neurology 38(7 Suppl 2): 29-30, 1988

Azathioprine in multiple sclerosis: the cons. Neurology 38(7 Suppl 2): 24-27, 1988

A closer look at plasmapheresis in multiple sclerosis: the cons. Neurology 38(7 Suppl 2): 53-56, 1988

Copolymer 1 as therapy for multiple sclerosis: the cons. Neurology 38(7 Suppl 2): 69-72, 1988

Experience with cyclophosphamide in multiple sclerosis: the cons. Neurology 38(7 Suppl 2): 14-18, 1988

Plasmapheresis in acute attacks of multiple sclerosis: the cons. Journal of Clinical Apheresis 6(4): 205-206, 1991

Treating multiple sclerosis with monoclonal antibodies: the cons. Neurology 38(7 Suppl 2): 47-49, 1988

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Current Medical Research and Opinion 31(7): 1349-1361, 2016

Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses. Patient Preference and Adherence 8: 1093-1099, 2014

Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis. Arquivos de Neuro-Psiquiatria 58(3a): 769-776, 2000

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment. Patient Preference and Adherence 10(): 659-667, 2016